JP2019502725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502725A5 JP2019502725A5 JP2018537803A JP2018537803A JP2019502725A5 JP 2019502725 A5 JP2019502725 A5 JP 2019502725A5 JP 2018537803 A JP2018537803 A JP 2018537803A JP 2018537803 A JP2018537803 A JP 2018537803A JP 2019502725 A5 JP2019502725 A5 JP 2019502725A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pge
- cell
- composition
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023000071A JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024219599A JP2025038093A (ja) | 2016-01-20 | 2024-12-16 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281064P | 2016-01-20 | 2016-01-20 | |
| US62/281,064 | 2016-01-20 | ||
| US201662402883P | 2016-09-30 | 2016-09-30 | |
| US62/402,883 | 2016-09-30 | ||
| PCT/US2017/014449 WO2017127755A1 (en) | 2016-01-20 | 2017-01-20 | Compositions and methods for immune cell modulation in adoptive immunotherapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000071A Division JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502725A JP2019502725A (ja) | 2019-01-31 |
| JP2019502725A5 true JP2019502725A5 (cg-RX-API-DMAC10.html) | 2020-02-27 |
| JP7653759B2 JP7653759B2 (ja) | 2025-03-31 |
Family
ID=59362155
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018537803A Active JP7653759B2 (ja) | 2016-01-20 | 2017-01-20 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2023000071A Pending JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024219599A Pending JP2025038093A (ja) | 2016-01-20 | 2024-12-16 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000071A Pending JP2023036919A (ja) | 2016-01-20 | 2023-01-04 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| JP2024219599A Pending JP2025038093A (ja) | 2016-01-20 | 2024-12-16 | 養子免疫療法における免疫細胞調節のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11413309B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3405568A4 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7653759B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017127755A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| AU2017210031C1 (en) * | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3417052B1 (en) * | 2016-02-16 | 2023-02-15 | Duke University | Methods for expanding and differentiating b cells for producing antibody |
| US11634686B2 (en) | 2016-11-01 | 2023-04-25 | Jian Feng | Method of producing naive pluripotent stem cells |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| CN118662615A (zh) | 2017-03-15 | 2024-09-20 | 浩康生物系统公司 | 用于造血干细胞移植的组合物和方法 |
| EP3600357A4 (en) | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| KR102382431B1 (ko) * | 2017-11-23 | 2022-04-01 | 베이징 이터널 머터리얼 테크놀로지 씨오., 엘티디 | 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| EP3914267A1 (en) | 2018-01-25 | 2021-12-01 | Mia Levite | Methods for improved immunotherapy |
| AU2019243315A1 (en) * | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| WO2020123447A1 (en) * | 2018-12-11 | 2020-06-18 | The Regents Of The University Of California | Compositions and methods for immunotherapies |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| EP3959305A1 (en) | 2019-04-26 | 2022-03-02 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| US20220213434A1 (en) | 2019-05-10 | 2022-07-07 | The Regents Of The University Of California | Modified pluripotent cells |
| EP4045648A4 (en) * | 2019-10-15 | 2023-11-22 | The Regents of The University of California | Transplanted cell protection via fc sequestration |
| CN110628717B (zh) * | 2019-10-28 | 2020-10-30 | 上海科医联创生物科技有限公司 | 一种浸润性t细胞的培养方法 |
| CN110592016B (zh) * | 2019-10-28 | 2020-10-02 | 上海科医联创生物科技有限公司 | 一种特异性t细胞的培养方法 |
| CN114867485A (zh) * | 2019-10-31 | 2022-08-05 | 全国儿童医院研究所 | Cd38敲除的原代和扩增的人nk细胞的生成 |
| JP7805928B2 (ja) | 2019-11-26 | 2026-01-26 | ノバルティス アーゲー | Cd19及びcd22キメラ抗原受容体及びその使用 |
| JP7879804B2 (ja) * | 2019-12-06 | 2026-06-24 | フェイト セラピューティクス,インコーポレイテッド | 小化合物を使用するiPSC由来エフェクター免疫細胞の増強 |
| US20230036952A1 (en) * | 2020-01-07 | 2023-02-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of producing t cell populations using induced pluripotent stem cells |
| KR20230040337A (ko) | 2020-06-19 | 2023-03-22 | 페이트 세러퓨틱스, 인코포레이티드 | 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합 |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| WO2022040504A2 (en) * | 2020-08-21 | 2022-02-24 | Georgetown University | Stem cell-like memory t cells and uses thereof |
| EP4228406A4 (en) | 2020-10-14 | 2024-11-13 | Ossium Health, Inc. | SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION |
| EP4229183A4 (en) | 2020-10-14 | 2024-12-11 | Ossium Health, Inc. | Compositions and methods for extraction of mesenchymal stem cells |
| EP4262831A4 (en) | 2020-12-18 | 2025-01-01 | Ossium Health, Inc. | CELLULAR THERAPY PROCESSES |
| CN114763563B (zh) * | 2021-01-12 | 2024-04-30 | 深圳华大临床检验中心 | 一种提高慢病毒感染效率的方法 |
| EP4288069A4 (en) * | 2021-02-07 | 2025-03-12 | Baylor College of Medicine | Engineered nkt cells for expansion and in vivo preservation and methods of use for the control of tumor cells |
| WO2022254337A1 (en) | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| KR20250004622A (ko) | 2022-04-08 | 2025-01-08 | 페이트 세러퓨틱스, 인코포레이티드 | 종양 표적화를 위한 키메라 항원 수용체 |
| KR20250005097A (ko) | 2022-04-08 | 2025-01-09 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양 표적화 골격을 갖는 세포 및 이의 용도 |
| WO2024211852A1 (en) * | 2023-04-07 | 2024-10-10 | Fate Therapeutics, Inc. | Ipsc-derived nk cell for lymphoma treatment |
| WO2024243325A2 (en) * | 2023-05-22 | 2024-11-28 | The Board Of Trustees Of The University Of Illinois | Combination of pac-1 and car t-cell treatments |
| CN116904400B (zh) * | 2023-09-12 | 2023-12-01 | 成都以邦医药科技有限公司 | 可利霉素在体外car/tcr-t细胞产品制备过程优化中的应用 |
| WO2025217183A1 (en) * | 2024-04-09 | 2025-10-16 | Board Of Regents, The University Of Texas System | Prepared natural killer cells and uses thereof |
| CN119161336B (zh) * | 2024-07-24 | 2025-09-05 | 四川大学 | 一种作为Blimp1抑制剂的小分子化合物及其用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2003455C (en) | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| HK1048302A1 (zh) | 1999-08-13 | 2003-03-28 | 大正制药株式会社 | 前列腺素衍生物 |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US20040175373A1 (en) * | 2002-06-28 | 2004-09-09 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| US20050075276A1 (en) | 2003-03-14 | 2005-04-07 | Christopher Rudd | Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| TWI441637B (zh) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
| WO2007103901A2 (en) | 2006-03-06 | 2007-09-13 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| CA2657227A1 (en) | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
| GB2444853B (en) | 2006-12-14 | 2010-02-24 | Medical Res Council | Methods & uses |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| AU2009322346B2 (en) | 2008-12-03 | 2015-07-02 | The Scripps Research Institute | Stem cell cultures |
| EP2375897A4 (en) * | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| WO2011159726A2 (en) | 2010-06-14 | 2011-12-22 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| JP5897035B2 (ja) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド,ボルチモア | 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法 |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| CA2977839C (en) | 2014-02-28 | 2022-07-26 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| WO2015155738A2 (en) | 2014-04-09 | 2015-10-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| RS61406B1 (sr) * | 2014-06-06 | 2021-03-31 | Bluebird Bio Inc | Poboljšane kompozicije t ćelija |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| CA2974903A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2980592A1 (en) | 2015-03-27 | 2016-10-06 | Nantkwest, Inc. | Nk-92 cells in combination therapy with cancer drugs |
| HK1247958A1 (zh) | 2015-05-05 | 2018-10-05 | 菲特治疗公司 | T淋巴细胞的调节 |
| CN107849102B (zh) | 2015-05-15 | 2022-05-13 | 希望之城 | 嵌合抗原受体组合物 |
| WO2017040324A1 (en) | 2015-08-28 | 2017-03-09 | The Trustees Of The University Of Pennsylvania | Methods and compositions for cells expressing a chimeric intracellular signaling molecule |
| CN122146606A (zh) | 2015-11-04 | 2026-06-05 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| AU2017210031C1 (en) * | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス,インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US11365392B2 (en) * | 2016-08-05 | 2022-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof |
| JP2019530470A (ja) * | 2016-08-05 | 2019-10-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | γδFoxp3+調節性T細胞のエクスビボ生成及びその治療的使用 |
| US11932870B2 (en) | 2016-12-05 | 2024-03-19 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3638775A1 (en) | 2017-06-13 | 2020-04-22 | Fate Therapeutics, Inc. | Compositions and methods for inducing myeloid suppressive cells and use thereof |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
-
2017
- 2017-01-20 JP JP2018537803A patent/JP7653759B2/ja active Active
- 2017-01-20 WO PCT/US2017/014449 patent/WO2017127755A1/en not_active Ceased
- 2017-01-20 US US16/071,460 patent/US11413309B2/en active Active
- 2017-01-20 EP EP17742065.0A patent/EP3405568A4/en active Pending
-
2022
- 2022-07-08 US US17/861,042 patent/US12419870B2/en active Active
-
2023
- 2023-01-04 JP JP2023000071A patent/JP2023036919A/ja active Pending
-
2024
- 2024-12-16 JP JP2024219599A patent/JP2025038093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528885A5 (cg-RX-API-DMAC10.html) | ||
| JP2025038093A5 (cg-RX-API-DMAC10.html) | ||
| JP2019502722A5 (cg-RX-API-DMAC10.html) | ||
| AU2021202391B2 (en) | Cells with increased immuno-regulatory properties and methods for their use and manufacture | |
| JP7653759B2 (ja) | 養子免疫療法における免疫細胞調節のための組成物および方法 | |
| JP7668781B2 (ja) | 幹細胞培養及び幹細胞治療用プライム化培地及びプライム化方法 | |
| IL293564A (en) | Enhancement of an effector immune cell, derived from an induced pluripotent stem cell, using small molecules | |
| US20190119635A1 (en) | Modulation of t lymphocytes | |
| JP7591406B2 (ja) | トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞 | |
| JP5745419B2 (ja) | 細胞、核酸構築物、前記構築物を含む細胞、及び疾患の治療において前記細胞を利用する方法 | |
| Zong et al. | GMP manufacturing of allogenic iPSC-NK cells for immunotherapy | |
| KR20250099777A (ko) | 전 세계, 민족 또는 질환 특이적 인구를 포괄하는 동종이계 세포 치료를 위한 면역 적합 세포 | |
| JP2025533909A (ja) | 多能性細胞に由来するb細胞系統 | |
| US20240050483A1 (en) | Methods for generating hematopoietic stem cells and compositions thereof | |
| CN118510525A (zh) | 产生nk细胞的方法 | |
| JP2024542151A (ja) | Nk細胞の生成法 | |
| JP7558952B2 (ja) | 中胚葉キラー(mk)細胞 | |
| WO2025125443A1 (en) | Production of immune cells | |
| Cardoso | Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? | |
| Roncarolo et al. | Role of IL-10 in Transplantation Tolerance |